Sepiapterin (Sephience) coverage
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.708 alerts
Get alerted when Policy CP.PHAR.708 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for Sephience (sepiapterin) for treatment of hyperphenylalaninemia (HPA) due to sepiapterin‑responsive phenylketonuria (PKU) across applicable QualChoice lines of business.
Updated diagnosis language to specify HPA due to PKU (rather than just PKU) to reflect FDA labeling.
Added requirement for documentation of member's current weight for dose calculation purposes.
Added requirement that member be adherent to a Phe‑restricted diet during treatment.
Added step therapy bypass for Illinois per IL HB 5395 (effective 01/01/2026) removing step requirement for Illinois HIM requests.
Coverage Criteria for Sephience (sepiapterin)
Requests for use of Sephience (sepiapterin) for indications that are not FDA‑approved under this policy are not authorized unless the provider submits sufficient supporting information per the applicable off‑label use policy or an evidence of coverage document. See off‑label policies CP.CPA.09 (Commercial), HIM.PA.154 (HIM/ICHRA), or CP.PMN.53 (Medicaid) for criteria that, if met, may allow coverage for non‑FDA indications.
Use of Sephience that does not meet the policy criteria is not authorized. Examples that typically result in denial include missing required documentation (diagnosis of HPA due to PKU, specialist prescriber or consult, recent Phe level ≥ 360 µmols/L, evidence of adherence to a Phe‑restricted diet, or current weight), lack of required prior sapropterin step trial when applicable, requests for concurrent use with sapropterin products or Palynziq, or requests for indications specifically listed as non‑FDA without off‑label justification. Providers must supply the documentation described in the policy to avoid denial.
Product Coding and Clinical Thresholds
| NDC not listed | Product availability: oral powder 250 mg, 1,000 mg (no NDC provided in policy) |
Provider Actions, Documentation, and Step Therapy
Prior authorization required; coverage only if policy criteria met
Prior authorization is required; Sephience (sepiapterin) is considered medically necessary only when the applicable initial or continuation criteria in this policy are met. Requests must demonstrate the member meets the policy criteria (e.g., diagnosis of HPA due to PKU, specialist prescriber/consult, required labs, diet adherence, weight, dosing limits).
Sapropterin (Kuvan) step required — Illinois HIM statutory bypass
A trial and documented failure of generic sapropterin (Kuvan) at up to maximally indicated doses is required prior to Sephience unless contraindicated or clinically significant adverse effects occur. Illinois HIM requests are exempt from the step therapy requirement per IL HB 5395 effective 1/1/2026.
Required documentation to support PA
Submit supporting clinical documentation with the PA request, including office chart notes and lab results showing diagnosis of HPA due to PKU, a recent (within 90 days) Phe blood level, evidence of adherence to a Phe‑restricted diet, documentation of prior sapropterin trial when applicable, and the member's current weight (kg) for dose calculation.
- Office/provider notes confirming diagnosis of HPA due to PKU and specialist involvement or consultation
- Recent Phe blood level report (within 90 days)
- Documentation of adherence to a Phe‑restricted diet and plan to continue it while on Sephience
- Records of prior sapropterin (Kuvan) trial and outcome, unless contraindicated or IL HIM bypass applies
- Member's current weight in kg for dose determination
Missing or insufficient documentation may lead to denial
Requests missing required elements (diagnosis of HPA due to PKU, a recent Phe blood level ≥ 360 µmols/L, evidence of adherence to a Phe‑restricted diet, documentation of prior sapropterin trial when applicable, or current weight) or for non‑FDA indications may be denied.
- No approval without documented diagnosis of HPA due to PKU
- No approval if recent Phe level is not provided or is < 360 µmols/L
- No approval if adherence to a Phe‑restricted diet is not documented
- No approval if current weight (kg) is not documented for dosing
- Non‑FDA indications require sufficient off‑label documentation per applicable off‑label policies
Initial Therapy — Decision Logic
Continuation Therapy — Decision Logic
Step Therapy Requirements
| Step | Requirement | Exceptions / Notes |
|---|---|---|
| {"text":"1","status":""}|{"text":"Trial and documented failure of generic sapropterin (Kuvan) at up to maximally indicated doses prior to approval of Sephience (sepiapterin).","status":""}|{"text":"Not required if sapropterin is contraindicated or causes clinically significant adverse effects; Illinois HIM requests are exempt from the step therapy requirement per IL HB 5395 effective 01/01/2026.","status":""} |
Dosing and Quantity Limits
Site of Care
No site‑of‑care restrictions
The policy does not impose any site‑of‑care restrictions.
Background and Product Information
Sephience (sepiapterin) is a phenylalanine hydroxylase (PAH) activator approved for the treatment of hyperphenylalaninemia (HPA) in patients aged ≥ 1 month with sepiapterin‑responsive phenylketonuria (PKU). It is intended to be used in conjunction with a Phe‑restricted diet to reduce blood phenylalanine levels. Product is supplied as oral powder in 250 mg and 1,000 mg packets; dosing is weight‑based per the prescribing information and rounded to the nearest 250 mg packet for dispensing.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.